DiaMedica Therapeutics Inc.

NASDAQ: DMAC · Healthcare · Biotechnology

PublicHQ Minneapolis, MN · HennepinCIK 0001401040Reports USD

#932 of 1,418 Healthcare companies by revenue

EA Score

35D

FH 37DQ 26GM —SS 61

v0.1 · 55/100 weight · provisional

↑ Altman-Z, market scale · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$32.8M

Employees

as of 2026-08-12

Market cap

$370.2M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$500.0k$500.0k2018

Net income-$32.8M-$32.8M2025

Operating income-$34.4M-$34.4M2025

Total assets$61.4M$61.4M2025

Equity$56.1M$56.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is DiaMedica Therapeutics Inc.’s revenue?

DiaMedica Therapeutics Inc. booked $500.0k in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -6553.2% net margin.

Peers · Healthcare

Lipella Pharmaceuticals Inc.——Sibannac, Inc.——Medivolve Inc.——Zenith Capital Corp.——Imunon, Inc.39D Bioelectronics Corporation——

Neighbors

Hennepin →

UnitedHealth Group Incorporated$447.6B80B+U.S. Bancorp$28.7B66B Target Corporation$104.8B81B+Ameriprise Financial, Inc.$18.9B72B Xcel Energy Inc.$11.5B67B General Mills, Inc.$18.4B67B

Key facts

CEODietrich John Pauls

SectorHealthcare

IndustryBiotechnology

HeadquartersMinneapolis, MN

ExchangeNASDAQ: DMAC

Employees35

IPO date2012-08-03

Latest filings

10-Q2026-08-10 8-K2026-08-10 8-K2026-05-21 8-K2026-05-06 10-Q2026-05-06 DEF 14A2026-04-01 8-K2026-03-31 10-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.